氨磺必利与奥氮平治疗精神分裂症首次发病患者的对照研究

目的:比较氨磺必利和奥氮平治疗精神分裂症的临床疗效和安全性。方法:将62例精神分裂症首次发病患者随机分为氨磺必利组和奥氮平组治疗8周。采用阳性与阴性症状量表(PANSS)于治疗前后评定疗效,并观察不良反应。结果:治疗8周两组PANSS总分减分及一般病理学减分比较差异无统计学意义;氨磺必利组PANSS阴性症状减分明显高于奥氮平组,奥氮平组PANSS阳性症状减分显著高于氨磺必利组(P均0.05)。氨磺必利组和奥氮平组总有效率分别为93.5%和96.8%,差异无统计学意义(P0.05)。奥氮平组体质量增加、镇静嗜睡和血糖升高发生率明显高于氨磺必利组(P0.05或P0.01)。结论:氨磺必利治疗精神分裂症的疗效与奥氮平相当,但不良反应相对较少。

A control study on amisulPride and olanzaPine in first ePisode Patients with schizoPhrenia

Objective：To compare the clinical efficacy and safety of amisulpride and olanzapine in first episode patients with schizophrenia. Method：Sixty-two first episode patients with schizophrenia were divided randomly into amisulpride group and olanzapine group,and received amisulpride and olanzapine respectively for 8 weeks. The positive and negative symptoms scale（PANSS）was used before and after treatment to evaluate the efficacy,and the side effects were observed. Results：After 8 weeks of treatment,the reduction of PANSS total score and general pathology score between the two groups were not statistically significant;the reducion of nega-tive symptoms score in amisulpride group was significantly higher than olanzapine group,while the reducion of positive symptoms score in olanzapine group was significantly higher than amisulpride group（all P ﹤ 0. 02）. The total efficiency in amisulpride group and olanzapine group were 93. 2% and 96. 8% respectively,and no significant difference between two groups（P ﹥ 0. 02）. The incidence of sedation or somnolence,weight gain and glucose enhance in olanzapine group were higher than the amisulpride group（P ﹤0. 02 or P ﹤0. 01）. Conclusion：Amisulpride is as effective as olanzapine for schizophrenia,but amisulpride has fewer side effects.